IL-10 and NOS2 Modulate Antigen-Specific Reactivity and Nerve Infiltration by T Cells in Experimental Leprosy

PLoS Neglected Tropical Diseases

Volumn 8, Issue 9, 2014, Pages

  Hagge, Deanna A ^a,b   Scollard, David M ^a   Ray, Nashone A ^a   Marks, Vilma T ^a   Deming, Angelina T ^a   Spencer, John S ^c   Adams, Linda B ^a  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b Anandaban Leprosy Hospital   (Nepal)

^c Department of Ecosystem Science and Sustainability   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOFERRITIN; EOTAXIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; ML0380; ML1877; ML2028; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDES AND PROTEINS; RANTES; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; NOS2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL VIABILITY; CD4+ CD44+ T LYMPHOCYTE; CD8+ CD44+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFLAMMATION; LEPROSY; MOUSE; MYCOBACTERIUM LEPRAE; NERVE INFILTRATION; NEUROLOGIC DISEASE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN INDURATION; T LYMPHOCYTE; ANIMAL; CD4+ T LYMPHOCYTE; DISEASE MODEL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE;

ANIMALS; ANTIGENS, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-10; LEPROSY; MICE; MICE, KNOCKOUT; MYCOBACTERIUM LEPRAE; NITRIC OXIDE SYNTHASE TYPE II;

EID: 84907572371     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003149     Document Type: Article

References (70)

1. Talhari S, Grossi MA, Oliveira ML, Gontijo B, Talhari C, et al. (2012) Hansen's disease: a vanishing disease? Mem Inst Oswaldo Cruz 107 Suppl 1: 13–16.
2. Duthie MS, Ireton GC, Kanaujia GV, Goto W, Liang H, et al. (2008) Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis. Clin Vaccine Immunol 15: 1590–1597.
3. Geluk A, Spencer JS, Bobosha K, Pessolani MC, Pereira GM, et al. (2009) From genome-based in silico predictions to ex vivo verification of leprosy diagnosis. Clin Vaccine Immunol 16: 352–359.
4. Geluk A, Bobosha K, van der Ploeg-van Schip JJ, Spencer JS, Banu S, et al. (2012) New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy. J Immunol 188: 4782–4791.
5. Lahiri R, Randhawa B, Franken KL, Duthie MS, Spencer JS, et al. (2011) Development of a mouse food pad model for detection of sub clinical leprosy. Lepr Rev 82: 432–444.
6. Pena M, Geluk A, Van Der Ploeg-Van Schip JJ, Franken KL, Sharma R, et al. (2011) Cytokine responses to Mycobacterium leprae unique proteins differentiate between Mycobacterium leprae infected and naive armadillos. Lepr Rev 82: 422–431.
7. Sampaio LH, Stefani MM, Oliveira RM, Sousa AL, Ireton GC, et al. (2011) Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis 11: 26.
8. Spencer JS, Dockrell HM, Kim HJ, Marques MA, Williams DL, et al. (2005) Identification of specific proteins and peptides in Mycobacterium leprae suitable for the selective diagnosis of leprosy. J Immunol 175: 7930–7938.
9. Spencer JS, Kim HJ, Wheat WH, Chatterjee D, Balagon MV, et al. (2011) Analysis of antibody responses to Mycobacterium leprae phenolic glycolipid I, lipoarabinomannan, and recombinant proteins to define disease subtype-specific antigenic profiles in leprosy. Clin Vaccine Immunol 18: 260–267.
10. Spencer JS, Duthie MS, Geluk A, Balagon MF, Kim HJ, et al. (2012) Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy. Mem Inst Oswaldo Cruz 107 Suppl 1: 79–89.
11. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, et al. (2006) The continuing challenges of leprosy. Clin Microbiol Rev 19: 338–381.
12. Krahenbuhl J, Adams LB, (2000) Exploitation of gene knockout mice models to study the pathogenesis of leprosy. Lepr Rev 71 Suppl: S170–175.
13. Adams LB, Scollard DM, Ray NA, Cooper AM, Frank AA, et al. (2002) The study of Mycobacterium leprae infection in interferon-gamma gene–disrupted mice as a model to explore the immunopathologic spectrum of leprosy. J Infect Dis 185 Suppl 1: S1–8.
14. Hagge DA, Marks VT, Ray NA, Dietrich MA, Kearney MT, et al. (2007) Emergence of an effective adaptive cell mediated immune response to Mycobacterium leprae is not impaired in reactive oxygen intermediate-deficient mice. FEMS Immunol Med Microbiol 51: 92–101.
15. Hagge DA, Saunders BM, Ebenezer GJ, Ray NA, Marks VT, et al. (2009) Lymphotoxin-alpha and TNF have essential but independent roles in the evolution of the granulomatous response in experimental leprosy. Am J Pathol 174: 1379–1389.
16. Adams LB, Pena MT, Sharma R, Hagge DA, Schurr E, et al. (2012) Insights from animal models on the immunogenetics of leprosy: a review. Mem Inst Oswaldo Cruz 107 Suppl 1: 197–208.
17. Adams LB, Job CK, Krahenbuhl JL, (2000) Role of inducible nitric oxide synthase in resistance to Mycobacterium leprae in mice. Infect Immun 68: 5462–5465.
18. Cooper AM, Adams LB, Dalton DK, Appelberg R, Ehlers S, (2002) IFN-gamma and NO in mycobacterial disease: new jobs for old hands. Trends Microbiol 10: 221–226.
19. Franceschi DS, Mazini PS, Rudnick CC, Sell AM, Tsuneto LT, et al. (2009) Influence of TNF and IL10 gene polymorphisms in the immunopathogenesis of leprosy in the south of Brazil. Int J Infect Dis 13: 493–498.
20. Malhotra D, Darvishi K, Sood S, Sharma S, Grover C, et al. (2005) IL-10 promoter single nucleotide polymorphisms are significantly associated with resistance to leprosy. Hum Genet 118: 295–300.
21. Pereira AC, Brito-de-Souza VN, Cardoso CC, Dias-Baptista IM, Parelli FP, et al. (2009) Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for -819C/T in leprosy susceptibility. Genes Immun 10: 174–180.
22. Santos AR, Suffys PN, Vanderborght PR, Moraes MO, Vieira LM, et al. (2002) Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy. J Infect Dis 186: 1687–1691.
23. Settin A, Nassar S, Abdel-Latif A, Elbaz R, El-Mongy S, et al. (2007) Association of cytokine gene polymorphism with susceptibility and clinical types of leprosy. Int J Health Sci (Qassim) 1: 25–33.
24. Cardona-Castro N, Sanchez-Jimenez M, Rojas W, Bedoya-Berrio G, (2012) IL-10 gene promoter polymorphisms and leprosy in a Colombian population sample. Biomedica 32: 71–76.
25. Aggarwal S, Ali S, Chopra R, Srivastava A, Kalaiarasan P, et al. (2011) Genetic variations and interactions in anti-inflammatory cytokine pathway genes in the outcome of leprosy: a study conducted on a MassARRAY platform. J Infect Dis 204: 1264–1273.
26. Sreenivasan P, Misra RS, Wilfred D, Nath I, (1998) Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions. Immunology 95: 529–536.
27. Manandhar R, Shrestha N, Butlin CR, Roche PW, (2002) High levels of inflammatory cytokines are associated with poor clinical response to steroid treatment and recurrent episodes of type 1 reactions in leprosy. Clin Exp Immunol 128: 333–338.
28. Geluk A, van Meijgaarden KE, Wilson L, Bobosha K, van der Ploeg-van Schip JJ, et al. (2014) Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions. J Clin Immunol 34: 245–255.
29. Kang TJ, Yeum CE, Kim BC, You EY, Chae GT, (2004) Differential production of interleukin-10 and interleukin-12 in mononuclear cells from leprosy patients with a Toll-like receptor 2 mutation. Immunology 112: 674–680.
30. Suryadevara NC, Neela VS, Devalraju KP, Jain S, SivaSai KS, et al. (2013) Influence of Intron II microsatellite polymorphism in human toll-like receptor 2 gene in leprosy. Hum Immunol 74: 1034–1040.
31. Marques CS, Brito-de-Souza VN, Guerreiro LT, Martins JH, Amaral EP, et al. (2013) Toll-like receptor 1 N248S single-nucleotide polymorphism is associated with leprosy risk and regulates immune activation during mycobacterial infection. J Infect Dis 208: 120–129.
32. Truman RW, Krahenbuhl JL, (2001) Viable M. leprae as a research reagent. Int J Lepr Other Mycobact Dis 69: 1–12.
33. Lahiri R, Randhawa B, Krahenbuhl J, (2005) Application of a viability-staining method for Mycobacterium leprae derived from the athymic (nu/nu) mouse foot pad. J Med Microbiol 54: 235–242.
34. Martinez AN, Lahiri R, Pittman TL, Scollard D, Truman R, et al. (2009) Molecular determination of Mycobacterium leprae viability by use of real-time PCR. J Clin Microbiol 47: 2124–2130.
35. Davis GL, Ray NA, Lahiri R, Gillis TP, Krahenbuhl JL, et al. (2013) Molecular assays for determining Mycobacterium leprae viability in tissues of experimentally infected mice. PLoS Negl Trop Dis 7: e2404.
36. Truman RW, Andrews PK, Robbins NY, Adams LB, Krahenbuhl JL, et al. (2008) Enumeration of Mycobacterium leprae using real-time PCR. PLoS Negl Trop Dis 2: e328.
37. Hagge DA, Ray NA, Krahenbuhl JL, Adams LB, (2004) An in vitro model for the lepromatous leprosy granuloma: fate of Mycobacterium leprae from target macrophages after interaction with normal and activated effector macrophages. J Immunol 172: 7771–7779.
38. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, et al. (1997) Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276: 1420–1422.
39. Hunter SW, Rivoire B, Mehra V, Bloom BR, Brennan PJ, (1990) The major native proteins of the leprosy bacillus. J Biol Chem 265: 14065–14068.
40. Mehra V, Bloom BR, Bajardi AC, Grisso CL, Sieling PA, et al. (1992) A major T cell antigen of Mycobacterium leprae is a 10-kD heat-shock cognate protein. J Exp Med 175: 275–284.
41. Pessolani MC, Smith DR, Rivoire B, McCormick J, Hefta SA, et al. (1994) Purification, characterization, gene sequence, and significance of a bacterioferritin from Mycobacterium leprae. J Exp Med 180: 319–327.
42. Welch TM, Gelber RH, Murray LP, Ng H, O'Neill SM, et al. (1980) Viability of Mycobacterium leprae after multiplication in mice. Infect Immun 30: 325–328.
43. Kamath AB, Woodworth J, Xiong X, Taylor C, Weng Y, et al. (2004) Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection. J Exp Med 200: 1479–1489.
44. Scollard DM, (2008) The biology of nerve injury in leprosy. Lepr Rev 79: 242–253.
45. Harboe M, Aseffa A, Leekassa R, (2005) Challenges presented by nerve damage in leprosy. Lepr Rev 76: 5–13.
46. Spierings E, de Boer T, Wieles B, Adams LB, Marani E, et al. (2001) Mycobacterium leprae-specific, HLA class II-restricted killing of human Schwann cells by CD4+ Th1 cells: a novel immunopathogenic mechanism of nerve damage in leprosy. J Immunol 166: 5883–5888.
47. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, et al. (1991) Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254: 277–279.
48. Venturini J, Soares CT, Belone Ade F, Barreto JA, Ura S, et al. (2011) In vitro and skin lesion cytokine profile in Brazilian patients with borderline tuberculoid and borderline lepromatous leprosy. Lepr Rev 82: 25–35.
49. Palermo ML, Pagliari C, Trindade MA, Yamashitafuji TM, Duarte AJ, et al. (2012) Increased expression of regulatory T cells and down-regulatory molecules in lepromatous leprosy. Am J Trop Med Hyg 86: 878–883.
50. Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, et al. (2013) Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 339: 1448–1453.
51. Montoya D, Cruz D, Teles RM, Lee DJ, Ochoa MT, et al. (2009) Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe 6: 343–353.
52. Sieling PA, Abrams JS, Yamamura M, Salgame P, Bloom BR, et al. (1993) Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. J Immunol 150: 5501–5510.
53. Misra N, Selvakumar M, Singh S, Bharadwaj M, Ramesh V, et al. (1995) Monocyte derived IL 10 and PGE2 are associated with the absence of Th 1 cells and in vitro T cell suppression in lepromatous leprosy. Immunol Lett 48: 123–128.
54. Lima MC, Pereira GM, Rumjanek FD, Gomes HM, Duppre N, et al. (2000) Immunological cytokine correlates of protective immunity and pathogenesis in leprosy. Scand J Immunol 51: 419–428.
55. Fukutomi Y, Matsuoka M, Minagawa F, Toratani S, McCormick G, et al. (2004) IL-10 treatment of macrophages bolsters intracellular survival of Mycobacterium leprae. Int J Lepr Other Mycobact Dis 72: 16–26.
56. Fukutomi Y, Maeda Y, Matsuoka M, Makino M, (2009) Temperature dependency for survival of Mycobacterium leprae in macrophages. Nihon Hansenbyo Gakkai Zasshi 78: 7–16.
57. Stefani MM, Martelli CM, Gillis TP, Krahenbuhl JL, (2003) In situ type 1 cytokine gene expression and mechanisms associated with early leprosy progression. J Infect Dis 188: 1024–1031.
58. Iyer A, Hatta M, Usman R, Luiten S, Oskam L, et al. (2007) Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. Clin Exp Immunol 150: 210–216.
59. Murray PJ, Young RA, (1999) Increased antimycobacterial immunity in interleukin-10-deficient mice. Infect Immun 67: 3087–3095.
60. Jacobs M, Brown N, Allie N, Gulert R, Ryffel B, (2000) Increased resistance to mycobacterial infection in the absence of interleukin-10. Immunology 100: 494–501.
61. Jacobs M, Fick L, Allie N, Brown N, Ryffel B, (2002) Enhanced immune response in Mycobacterium bovis bacille calmette guerin (BCG)-infected IL-10-deficient mice. Clin Chem Lab Med 40: 893–902.
62. Redford PS, Boonstra A, Read S, Pitt J, Graham C, et al. (2010) Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol 40: 2200–2210.
63. Higgins DM, Sanchez-Campillo J, Rosas-Taraco AG, Lee EJ, Orme IM, et al. (2009) Lack of IL-10 alters inflammatory and immune responses during pulmonary Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 89: 149–157.
64. Gomes MS, Florido M, Pais TF, Appelberg R, (1999) Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene. J Immunol 162: 6734–6739.
65. Ehlers S, Kutsch S, Benini J, Cooper A, Hahn C, et al. (1999) NOS2-derived nitric oxide regulates the size, quantity and quality of granuloma formation in Mycobacterium avium-infected mice without affecting bacterial loads. Immunology 98: 313–323.
66. Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, et al. (2007) Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis 44: 33–40.
67. Antunes DE, Araujo S, Ferreira GP, Cunha AC, Costa AV, et al. (2013) Identification of clinical, epidemiological and laboratory risk factors for leprosy reactions during and after multidrug therapy. Mem Inst Oswaldo Cruz 108: 901–908.
68. de Oliveira DT, Sherlock J, de Melo EV, Rollemberg KC, da Paixao TR, et al. (2013) Clinical variables associated with leprosy reactions and persistence of physical impairment. Rev Soc Bras Med Trop 46: 600–604.
69. Xolalpa W, Vallecillo AJ, Lara M, Mendoza-Hernandez G, Comini M, et al. (2007) Identification of novel bacterial plasminogen-binding proteins in the human pathogen Mycobacterium tuberculosis. Proteomics 7: 3332–3341.
70. Lahteenmaki K, Edelman S, Korhonen TK, (2005) Bacterial metastasis: the host plasminogen system in bacterial invasion. Trends Microbiol 13: 79–85.